# BXOS110 Injection in the Treatment of Acute Ischaemic Stroke

> **NCT06322394** · PHASE2 · UNKNOWN · sponsor: **Biocells (Beijing) Biotech Co.,Ltd** · enrollment: 300 (estimated)

## Conditions studied

- Acute Ischemic Stroke

## Interventions

- **DRUG:** high-dose BXOS110
- **DRUG:** low-dose BXOS110
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06322394
- **Lead sponsor:** Biocells (Beijing) Biotech Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-02-07
- **Primary completion:** 2025-03
- **Final completion:** 2025-09
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2024-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06322394

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06322394, "BXOS110 Injection in the Treatment of Acute Ischaemic Stroke". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06322394. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*